23:26 , Nov 13, 2018 |  BC Extra  |  Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
02:13 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

Vapendavir: Ph IIb SPIRITUS data

Top-line data from the double-blind, international Phase IIb SPIRITUS trial in 168 evaluable patients ages 18-70 with moderate to severe asthma and laboratory-confirmed HRV infection showed that twice-daily 264 and 528 mg doses of oral...
01:26 , Jan 6, 2017 |  BC Innovations  |  Product R&D

Viral ambitions

  Meissa Vaccines Inc. is translating studies from an Emory University team into a pair of vaccine platforms to protect specific at-risk subpopulations from infections by two otherwise innocuous viruses, RSV and the common cold....
23:11 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Non-human primate studies suggest a polyvalent inactivated human rhinovirus (HRV) vaccine could help prevent HRV infection. The vaccine consisted of 50 formalin-inactivated HRV strains expressing a range of differing HRV capsids, plus...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Georgia State University, Aviragen deal

Georgia State granted Aviragen exclusive, worldwide rights to co-develop and commercialize a portfolio of next-generation respiratory syncytial virus (RSV) replication inhibitors discovered by the university. The partners did not respond to inquiries. Georgia State University...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase IIa suspended enrollment

Aviragen voluntarily suspended enrollment in a double-blind, placebo-controlled, U.K. Phase IIa trial of oral BTA585 after 1 subject had “an increase of a cardiac enzyme level coupled with transient ECG changes,” which led to their...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Aviragen, HealthCare Royalty Partners deal

Aviragen sold an undisclosed portion of its Inavir laninamivir octanoate royalty rights to HealthCare Royalty Partners for $20 million. Aviragen said it receives about $4.5 million annually from Inavir royalties. Daiichi Sankyo Co. Ltd. (Tokyo:4568,...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase IIa started

Aviragen (formerly Biota Pharmaceuticals Inc. ) began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 100 mg oral BTA585 twice daily for 7 days in about 60 healthy adult volunteers challenged intranasally with RSV....
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase I data

Top-line data from a placebo-controlled, U.S. Phase I trial in 36 healthy volunteers showed that twice-daily 100, 400 and 600 mg doses of oral BTA585 were generally well tolerated with no serious adverse events reported....
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

BTA074: Phase II started

Biota began a double-blind, placebo-controlled, South American Phase II trial to evaluate topical BTA074 5% gel twice daily for up to 16 weeks in about 210 patients with anogenital warts caused by HPV types 6...